news, journals and articles from all over the world.
Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs)—prescription medications sold under popular drug names like Ozempic and Wegovy—in the United States.
A nationwide study found a marked increase in new GLP-1RA prescriptions over the last decade, particularly since 2020. Semaglutide was the most prescribed GLP-1RA, by far, in 2023.
Weight-loss drugs are all over the news these days. A Penn State Health expert helps separate fact from fiction and determine what’s the safest alterative for the people who need them.
Christian Hendershot, PhD, associate professor of psychiatry and director of the Clinical and Translational Addiction Research Program at the UNC School of Medicine, presented early findings from the first completed randomized controlled trial of semaglutide for reducing alcohol consumption in heavy drinkers.
A study of persons with HIV (PWH) and metabolic dysfunction–associated steatotic liver disease, also known as ‘fatty liver disease,’ (MASLD) found that semaglutide was highly effective at reducing liver fat and cardiovascular disease risk in this population.
On March 8, the U.S. Food and Drug Administration approved a new indication for the use of semaglutide (brand Wegovy) to “reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or…
New weight-loss drugs have helped people with their diabetes, obesity, even high blood pressure. But how they affect our mental health is a much more complicated issue, says Dr. Carrie McAdams, a psychiatrist and eating disorders expert at UT Southwestern…
More than 37 million Americans have been diagnosed with diabetes, with another 8.5 million believed to be living with the condition undiagnosed. In addition, 38 percent of the United States adult population is estimated to have prediabetes, a serious condition…
Nonalcoholic steatohepatitis (NASH)-related cirrhosis can lead to serious liver-related outcomes. In a phase 2 trial, lead author Rohit Loomba, MD, University of California San Diego School of Medicine, and collaborators, report semaglutide 2.4 mg once weekly in patients with NASH-related cirrhosis…
Rowena Roque, 46, was having a problem that many people can relate to: doing everything in her power to lose weight and get healthy but never succeeding.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu